Should patients with chronic obstructive pulmonary disease be vaccinated against pneumococcal diseases?

Expert Review of Respiratory Medicine

Volumn 3, Issue 6, 2009, Pages 585-596

  Gaillat, Jacques ^a  

^a Centre Hospitalier de la Region d'Annecy   (France)

Author keywords

Chronic obstructive pulmonary disease; Pneumococcal vaccination; Pneumococcus

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE;

CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MORTALITY; PNEUMOCOCCAL INFECTION; PREVALENCE; REVIEW; STATISTICAL ANALYSIS; VACCINATION;

EID: 73549102176     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.53     Document Type: Review

References (71)

1. Fine MJ, Smith MA, Carson CA et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch. Intern. Med. 154(23), 2666-2677 (1994). • First meta-analysis on the efficacy of the polysaccharidic vaccine. It established its efficacy in invasive diseases but was controversial for its efficacy in at-risk patients.
2. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 180(1), 48-58 (2009). •• Latest meta-analysis at the WHO's request shows that the studies with the best method did not show evidence of efficacy, particularly in at-risk patients. Despite these conclusion, the WHO did not change its recommendations.
3. Granger RH, Walters JAE, Poole P et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 4, CD001390 (2006). • A single meta-analysis in chronic obstructive pulmonary disease (COPD) patients. The effectiveness results are too low to be conclusive
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349, 1498-1504 (1997).
5. Rabe KF, Hurd S, Antonio Anzueto A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 176, 532-555 (2007).
6. Murtagh E, Heaney L, Gingle J, Sheperd R et al. Prevalence of obstructive lung disease in a general population sample: the NICECOPD study. Eur. J. Epidemiol. 20, 443-453 (2005).
7. Chen Y, Steward P, Dules R, Johansen H, Bryan S, Taylor G. Changing age-pattern of hospitalization of chronic obstructive pulmonary disease in men and women in Canada. Age Ageing 34, 373-377 (2005).
8. Alfageme I, Vazquez R, Reyes N et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61, 189-195 (2006). •• The best randomized study of COPD patients with a population large enough to give some impact to the results.
9. Mannino DM , Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Resp. Med. 103, 224-229 (2009).
10. Jackson ML, Neuzil KM, Thompson W et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin. Infect. Dis. 39, 1642-1650 (2004).
11. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low risk patients with community-acquired pneumonia. N. Engl. J. Med. 336, 243-250 (1997).
12. Torres A, Menendez R. Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Eur. Respir. J. 28, 262-263 (2006).
13. Roson B, Carratala J, Dorca J, Casanova A, Mansera F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin. Infect. Dis. 33, 158-165 (2001).
14. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur. Resp. J. 28, 346-351 (2008).
15. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 117(Suppl. 2), 380S-385S (2000).
16. Saint S, Flaherty KR, Abrahamse P et al. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy. Clin. Ther. 23, 499-512 (2001).
17. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 2355-2365 (2008).
18. Ko FW, Ip M, Chan PK, Ng SS, Chau SS, Hui DS. A one year-prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Resp. Med. 102, 1109-1116 (2008).
19. Hutchison BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Can. Fam. Phys. 45, 2381-2393 (1999).
20. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam. Pract. 1, 1 (2000). • Probably the meta-analysis with the most conflicting results, showing no effect at all of the pneumococcal vaccine (PPV).
21. Cornu C, Yzèbes D, Léophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 19, 4780-4790 (2001). • First meta-analysis to show a reduction in mortality.
22. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 20, 2166-2173 (2002).
23. Dear KB G, Andrews R, Holden J, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 4, CD000422 (2003).
24. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur. J. Epidemiol. 19, 353-363 (2004). • This meta-analysis is also a comprehensive review of the different meta-analyses published before it. It gives argument to show efficacy in the elderly, and the economical aspect is also considered in part II.
25. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 3, CD000422 (2007).
26. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 22, 927-946 (2004). • The purpose of this paper is to show the limitations of the meta-analysis. The size of the population is particularly well exposed.
27. Smith MD, Sheppard CL, Hogan A et al.; South West Pneumococcus Study Group. Diagnosis of Streptococcus pneumoniae infections in adults with bacteremia and community-acquired pneumonia: clinical comparison of pneumococcal PCR and urinary antigen detection. J. Clin. Microbiol. 47, 1046 (2009).
28. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325, 1453-1460 (1991). •• Probably one of the best prospective cohort studies confirming the effectiveness as close to 60% in invasive diseases in nonimmunosuppressed patients, either elderly or not. But in immunocompromised patients, the protective effectiveness was 21%. The authors have also shown a more rapid decline in antibody levels in elderly patients (>75 years of age).
29. Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 22, 3214-3224 (2004).
30. Jackson L, Neuzil M, Yu O et al. Effectiveness of polysaccharide pneumococcal vaccine in older adults. N. Engl. J. Med. 348, 1747-1755 (2003).
31. Dominguez A, Salleras L, Fedson D et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case control study. Clin. Infect. Dis. 40, 1250-1257 (2005).
32. Skull SA, Andrews RM, Byrnes GB. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine 25, 4631-4640 (2007).
33. Vila-Corcoles A, Ochoa-Gondar O, Hospital I et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin. Infect. Dis. 43, 860-868 (2006). •• A recent, well-done and rare study on pneumonia and not only systemic infections. Results are also shown to subpopulations with different level of risk, particularly COPD patients.
34. Landesman SH, Slith P, Shiffman G. Pneumococcal vaccine in elderly patients with COPD. Chest 84, 433-435 (1983).
35. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 136, 361-365 (1987).
36. Davis A, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. Chest 92(22), 204-212 (1987).
37. Musher D, Luchi MJ, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and olders bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J. Infect. Dis. 161, 728-735 (1990).
38. Rubins JB, Puri A K, Loch J et al. Magnitude, duration, quality and function of pneumococcal vaccine responses in elderly adults. J. Infect. Dis. 178, 431-440 (1998).
39. Chen M, Hisatomi Y, Furumoto A et al. Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin. Vaccin. Immunol. 14(2), 139-145 (2007).
40. Lai CC, Lee LN, Yu CJ et al. Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease. J. Formos Med. Assoc. 3, 196-203 (2007).
41. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistance of antibodies to pneumococcal polysaccharide vaccine in the elderly. J. Infect. Dis. 176, 1100-1104 (1997).
42. Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease: the effect of ongoing, systemic steroid treatment. Vaccine 24, 1408-1412 (2006).
43. Romero-Steiner S, Musher D, Cetron MS et al. Reduction in functional activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29, 281-288 (1999).
44. Schenkein J, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency Vaccine 26, 5521-5526 (2008).
45. Ochoa-Gondar O, Vila-Corcoles A, Ansa X. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine 26, 1955-1962 (2008).
46. Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J. Gen. Int. Med. 22, 62-67 (2007).
47. Vila-Corcoles A, Salsench E, Rodriguez-Blanco T et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 27, 1504-1510 (2009).
48. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung diseases. Vaccine 17, S91-S93 (1999).
49. Sumitani M, Tochino Y, Kamimori T, Fujiwara H, Fujikawa T. Additive inoculation of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients. Int. Med. 47, 1189-1197 (2008).
50. Furumoto, Ohkusa Y, Chen M et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 26, 4284-4289 (2008).
51. Musher DM, Rueda-Jaimes AM, Edward A, Graviss EA, Rodriguez-Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin. Infect. Dis. 43, 1004-1008 (2006).
52. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2003. Can. Respir. J. 10(Suppl. A), 5A-65A (2003).
53. Woodhead M, Blasi F, Ewig S. ERS Task Force in Collaboration with ESCMID. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 26, 1138-1180 (2005).
54. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society. Consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44, S27-S72 (2007).
55. Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe. Eurosurveillance 10, 174-178 (2005). • Interesting study comparing the policy of different European countries based on the same data from the literature. It shows how the differences are important between countries with the same economical levels.
56. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737-1746 (2003). •• First, and later largely confirmed, study in different states in the USA or in other countries to show the important impact of toddler vaccination on the elderly to reduce invasive infections. It shows the role of the reduction of Streptococcus pneumoniae colonization into herd immunity.
57. Isaacman DJ, Fletcher M, Fritzel B, Ciuryla B, Schranz J. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine. Vaccine 25, 2420-2427 (2007).
58. Hammit LL, Bruden DL, Butler JC et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal diseases. J. Infect. Dis. 193, 1487-1494 (2006).
59. Grijalva CG, Nuorti P, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time series analysis. Lancet 369, 1179-1186 (2007). •• First paper to show the indirect impact of conjugated PPVs to not only reduce invasive diseases but also pneumonia in adults.
60. Haber M, Baskey A, Baughman W et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 25, 5390-5398 (2007).
61. Mooney JD, Weir A, McMenamin J et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect. Dis. 8(53), 1-12 (2008).
62. De Roux A, Schmoele-Thoma B, Siber GR et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin. Infect. Dis. 46, 1015-1023 (2008). •• Important paper, which not only shows a better response in the elderly with a conjugated vaccine, particularly with opsonophacytosis, but also the possibility of hyporesponsiveness after a first dose of polysaccharide vaccine followed by a conjugated vaccine. A former polysaccharide vaccination must be considered in forthcoming studies in adults.
63. O'Brien KL, Hachmann M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccine: is hyporesponsiveness an issue? Lancet Infect. Dis. 7, 597-606 (2007).
64. Jackson LA, Neuzil KM, Nahm MH et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 25, 4029-4037 (2007).
65. Dransfield MK, Nahm MH, Kan MK et al. Superior immune response to proteinconjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180, 499-505 (2009).
66. Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit. Rev. Microbiol. 32, 139-153 (2006) •• Very comprehensive review of the different possibilities of protein candidate vaccines.
67. Rajam G, Anderton JM, Carlone GM, Sampson JS, Ades EW. Pneumococcal surface adhesion A (PsaA): a review. Clin. Rev. Microbiol. 34, 163-173 (2008).
68. Cao J, Li D, Gong Y et al. Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin. Exp. Immunol. 156(1), 52-60 (2009).
69. WHO. World Health Report 2002 www.who.int/whr/2002
70. National Heart, Lung and Blood Institute. Morbidity and mortality: 2002 chartbook on cardiovascular, lung and blood diseases. Bethesda, MD, USA: US department of Health and Human Services National Institutes of Health. May (2002) http://nhlbi.nih.gov/ressources/doc/02-chtbk.pdf
71. WHO Weekly Epidemiological Record 42, 373-384 (2008) www.who.int/wer